TSLP and chronic myelogenous leukemia, BCR-ABL1 positive: For example, the inhibition of TSLP, an inhibitory target of atopic dermatitis, was predicted to lead to therapeutic effects in cervical cancer (CC), ovarian cancer (OC), systemic lupus erythematosus (SLE), chronic myeloid leukemia (CML) and congenital muscular dystrophies.